Laboratorios Rovi : Q3 2024 preview. CDMO business gains momentum
>Improving sales momentum driven by the CDMO unit. Underlying prescription pharma evolution remains solid - The company is due to publish its Q3 2024 results on 7 November before the market opens (no conference call). We expect a sequential sales momentum improvement, jumping 6% y-o-y to € 227m (vs 0% in Q2, -25% in Q1 and -3% in Q4), which is explained by a strong CDMO evolution (flattish vs Q3 2023 which was the unit’s second best quarter ever) which was favoured b...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.